How PTEN Loss Hides Colon Tumors From the Immune System
A newly discovered molecular pathway explains why many colorectal cancers resist immunotherapy — and points to a druggable target.
Summary
Immunotherapy works poorly in most colorectal cancers, and scientists have long sought to understand why. This study reveals that loss of a common tumor suppressor gene called PTEN — absent in up to a third of these cancers — triggers a chain reaction that strips cancer cells of a molecular flag that immune cells use to find and destroy them. Without this flag, called MHC-I, killer T-cells cannot recognize the tumor. The researchers identified the exact molecular steps involved and showed that blocking a key protein in this pathway with an existing drug restored immune visibility and made tumors respond to checkpoint immunotherapy in preclinical models. The findings suggest that testing colorectal cancer patients for PTEN loss could help identify who might benefit from this combination approach.
Detailed Summary
Immunotherapy has transformed cancer treatment, but microsatellite stable (MSS) colorectal cancer — the most common subtype — remains stubbornly resistant to immune checkpoint blockade. Understanding why is a major clinical priority, since MSS colorectal cancer kills hundreds of thousands of people annually.
This study from Sun Yat-sen University focused on PTEN, a tumor suppressor gene lost in 19–36% of MSS colorectal cancer cases. Researchers combined analysis of patient cohorts, The Cancer Genome Atlas database, single-cell RNA sequencing, and detailed molecular experiments to trace exactly how PTEN loss enables tumors to hide from the immune system.
The key discovery was a previously unknown function of PTEN: it physically binds to and stabilizes a protein called KEAP1, protecting it from degradation. When PTEN is absent, KEAP1 breaks down, which unleashes a transcription factor called NRF2. Hyperactive NRF2 then ramps up a selective autophagy program that targets MHC-I — the surface molecule that displays tumor antigens to CD8+ T-cells — for lysosomal destruction. With MHC-I gone from the cell surface, killer T-cells can no longer identify and attack the tumor.
Critically, the team showed that a pharmacological NRF2 inhibitor called ML385 restored MHC-I surface expression and, in PTEN-deficient tumor models, sensitized tumors to anti-PD-1 therapy — a widely used immunotherapy drug class.
For clinicians, these findings suggest that PTEN status could serve as a biomarker for selecting patients who might benefit from NRF2 inhibition combined with checkpoint immunotherapy. For researchers, the newly identified PTEN–KEAP1 interaction represents a non-canonical tumor suppressor function with broad implications.
Caveats include that this summary is based on the abstract only, and preclinical findings require validation in clinical trials before translation to patient care.
Key Findings
- PTEN loss in MSS colorectal cancer strongly correlates with reduced CD8+ T-cell infiltration and worse survival on immunotherapy.
- PTEN stabilizes KEAP1 via its C2 domain; without PTEN, KEAP1 degrades and NRF2 becomes hyperactive.
- NRF2 hyperactivation drives selective autophagy that destroys MHC-I, stripping tumor cells of immune recognition signals.
- NRF2 inhibitor ML385 restored MHC-I surface levels and sensitized PTEN-deficient tumors to anti-PD-1 therapy in preclinical models.
- PTEN status could serve as a predictive biomarker for immunotherapy response in colorectal cancer patients.
Methodology
The study used an integrative design combining clinical cohort analysis, TCGA database mining, single-cell RNA sequencing, and flow cytometry to map the tumor immune microenvironment. Mechanistic dissection employed immunohistochemistry, mass spectrometry, co-immunoprecipitation, and confocal microscopy. Pharmacological rescue experiments with ML385 were conducted in PTEN-deficient tumor models.
Study Limitations
This summary is based on the abstract only, as the full text was not accessible, so methodological details and data quality cannot be fully assessed. The pharmacological rescue experiments appear to be preclinical, and efficacy in human clinical trials has not yet been demonstrated. The generalizability of these findings to other PTEN-deficient cancer types is not yet established.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.